Pharmacy Medical News about Proteasome Inhibitors

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Statins and cancer risk

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Proteasome Inhibitors in Cancer Therapy
Current Drug Targets, 10/23/09

Testa U – The studies have lead to a new generation of proteasome inhibitors, some of them exhibiting the property of selective proteasome inhibition and efficacy in cancer therapy without inducing the side effects elicited by bortezomib. The ensemble of these drugs offers the scenario of the possible development of a family of proteasome inhibitors, contributing a drug arsenal for the therapy of cancer and other diseases.

<< Previous
Inflammatory Systemic Biomarkers in Setting Acute Coronary...

Next >>
Severe Apnea in an Infant Exposed to Lamotrigine in Breast Milk

Histone deacetylase inhibitors induce thyroid cancer-specific apoptosis through proteasome-dependent inhibition of TRAIL degradation
Oncogene, 10/08/09 Relevance Score: 68%

The Proteasome Inhibitor Bortezomib Enhances the Susceptibility to Viral Infection
Journal of Immunology, 11/13/09 Relevance Score: 67%

Proteasome inhibitors activate autophagy as a cytoprotective response in human prostate cancer cells
Oncogene, 11/05/09 Relevance Score: 67%

SC68896, a Novel Small Molecule Proteasome Inhibitor, Exerts Antiglioma Activity In vitro and In vivo
Clinical Cancer Research, 10/26/09 Relevance Score: 66%

BU-32: a novel proteasome inhibitor for breast cancer
Breast Cancer Research, 10/15/09 Relevance Score: 65%